Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALUMIS INC.ALMS · Entity 4816 | Director · 10% owner · See Remarks | May 21, 2025 | May 23, 2025 |
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director · See Remarks | March 08, 2021 | March 11, 2021 |
| POPULAR, INC.BPOP · Entity 1363 | Director | May 08, 2018 | May 10, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALUMIS INC.
Report date May 21, 2025 · Filed May 23, 2025
Jointly reported with AyurMaya Capital Management Company, LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per share ("Common Stock")SEC Table I · non-derivative | IndirectSee footnotes | 15,139,707 |
Reported balance
After 2025-05-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 4,493,741 · Balance 15,139,707 F1: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement. F2: Reflects the estimated number of shares of Common Stock to be issued to the AyurMaya Fund (as defined below) pursuant to the Merger Agreement. The Reporting Persons will file an amendment to this Form 4 to the extent the actual number of shares of Common Stock issued differs in any material respect from the number reported in column (4). F3: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement.
F2: Reflects the estimated number of shares of Common Stock to be issued to the AyurMaya Fund (as defined below) pursuant to the Merger Agreement. The Reporting Persons will file an amendment to this Form 4 to the extent the actual number of shares of Common Stock issued differs in any material respect from the number reported in column (4).
F3: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.
F4: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.
Adaptive Biotechnologies Corp
Report date March 08, 2021 · Filed March 11, 2021
Jointly reported with Matrix Capital Management Company, LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 12,309,090 |
Last balance in matching sequence
After 2021-03-10 transaction · row 9
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
9 source rowsRow 1 · 2021-03-08 · Sale · Disposed 234,295 · Balance 12,880,795 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Row 2 · 2021-03-08 · Sale · Disposed 75,000 · Balance 12,805,795 F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Row 3 · 2021-03-08 · Sale · Disposed 33,600 · Balance 12,772,195 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Row 4 · 2021-03-08 · Sale · Disposed 71,194 · Balance 12,701,001 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Row 5 · 2021-03-08 · Sale · Disposed 85,911 · Balance 12,615,090 F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Row 6 · 2021-03-09 · Sale · Disposed 215,698 · Balance 12,399,392 F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Row 7 · 2021-03-09 · Sale · Disposed 34,302 · Balance 12,365,090 F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Row 8 · 2021-03-10 · Sale · Disposed 25,732 · Balance 12,339,358 F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Row 9 · 2021-03-10 · Sale · Disposed 30,268 · Balance 12,309,090 F9: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 1,504 |
Reported balance
Holding disclosure · report date 2021-03-08 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 1,504 F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F9: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F10: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.
F11: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
POPULAR, INC.
Report date May 08, 2018 · Filed May 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Par Value $0.01 per shareSEC Table I · non-derivative | Direct | 12,828.433 |
Reported balance
After 2018-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-08 · Grant · Acquired 2,133 · Balance 12,828.433 F1: Award of Restricted Stock pursuant to Popular, Inc.'s 2004 Omnibus Incentive Plan. The restriction of such restricted stock award lapses upon the retirement of the director. F2: Includes 122.79 shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock pursuant to Popular, Inc.'s 2004 Omnibus Incentive Plan. The restriction of such restricted stock award lapses upon the retirement of the director.
F2: Includes 122.79 shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Jointly reported with AyurMaya Capital Management Company, LP
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per share ("Common Stock")SEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 9,334,735 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among Alumis Inc., a Delaware corporation ("Alumis") and ACELYRIN, Inc., a Delaware corporation (the "Issuer") and the other parties thereto, each share of Common Stock was cancelled and converted into the right to receive 0.4274 shares of Common Stock, without interest and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding. F2: The securities reported herein were held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among Alumis Inc., a Delaware corporation ("Alumis") and ACELYRIN, Inc., a Delaware corporation (the "Issuer") and the other parties thereto, each share of Common Stock was cancelled and converted into the right to receive 0.4274 shares of Common Stock, without interest and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding.
F2: The securities reported herein were held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager.
F3: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.
Aura Biosciences, Inc.
Report date May 07, 2026 · Filed May 11, 2026
Jointly reported with Matrix Capital Management Company, LP
Section 16 reporting ended · disclosed 2026-05-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per share (Common Stock)SEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2026-05-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-05-07 · Sale · Disposed 6,922,870 · Balance 0 F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.
F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Zentalis Pharmaceuticals, Inc.
Report date December 15, 2025 · Filed December 15, 2025
Jointly reported with Matrix Capital Management Company, LP
Section 16 reporting ended · disclosed 2025-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 6,459,973 |
Reported balance
After 2025-12-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-15 · Sale · Disposed 7,500,000 · Balance 6,459,973 F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.
F2: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 11, 2026 20:16 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock, par value $0.00001 per share (Common Stock) | 6,922,870 | $5.64 | $39,044,986.80 |
DisclosureSEC source: 0000950142-26-001346 · es260777872_4-matrix.xml · nonDerivative · entry 1 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| December 15, 2025 Filed Dec 15, 2025 22:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock, par value $0.001 per share | 7,500,000 | $1.33 | $9,975,000.00 |
DisclosureSEC source: 0000902664-25-005288 · ownership.xml · nonDerivative · entry 1 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,459,973 F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:20 UTC | ALUMIS INC. ALMS · Entity 4816 | GrantCommon Stock, par value $0.0001 per share ("Common Stock") | 4,493,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-25-002532 · ownership.xml · nonDerivative · entry 1 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 15,139,707 F1 · kind: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement. F2 · shares: Reflects the estimated number of shares of Common Stock to be issued to the AyurMaya Fund (as defined below) pursuant to the Merger Agreement. The Reporting Persons will file an amendment to this Form 4 to the extent the actual number of shares of Common Stock issued differs in any material respect from the number reported in column (4). F1 · price: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement. F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:23 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Disposition to issuerCommon Stock, par value $0.00001 per share ("Common Stock") | 9,334,735 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-25-002533 · ownership.xml · nonDerivative · entry 1 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among Alumis Inc., a Delaware corporation ("Alumis") and ACELYRIN, Inc., a Delaware corporation (the "Issuer") and the other parties thereto, each share of Common Stock was cancelled and converted into the right to receive 0.4274 shares of Common Stock, without interest and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding. F1 · price: Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among Alumis Inc., a Delaware corporation ("Alumis") and ACELYRIN, Inc., a Delaware corporation (the "Issuer") and the other parties thereto, each share of Common Stock was cancelled and converted into the right to receive 0.4274 shares of Common Stock, without interest and, if applicable, cash in lieu of fractional shares, subject to any applicable withholding. F2 · ownership.nature: The securities reported herein were held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:45 UTC | ALUMIS INC. NASDAQ · Entity 4816 | ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 12,745,916 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-24-004603 · ownership.xml · derivative · entry 5 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,726,398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F1 · derivative.exercise_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F1 · derivative.expiration_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:45 UTC | ALUMIS INC. NASDAQ · Entity 4816 | ConversionSeries B-2 Redeemable Convertible Preferred Stock · Derivative | 5,336,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-24-004603 · ownership.xml · derivative · entry 4 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,141,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F1 · derivative.exercise_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F1 · derivative.expiration_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:45 UTC | ALUMIS INC. NASDAQ · Entity 4816 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 20,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-24-004603 · ownership.xml · derivative · entry 3 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 4,278,074 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F1 · derivative.exercise_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F1 · derivative.expiration_date: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:45 UTC | ALUMIS INC. NASDAQ · Entity 4816 | GrantCommon Stock | 2,500,000 | $16.00 | $40,000,000.00 |
DisclosureSEC source: 0000902664-24-004603 · ownership.xml · nonDerivative · entry 2 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 10,645,966 F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:45 UTC | ALUMIS INC. NASDAQ · Entity 4816 | ConversionCommon Stock, par value $0.0001 per share ("Common Stock") | 8,145,966 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-24-004603 · ownership.xml · nonDerivative · entry 1 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · 10% owner · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 8,145,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F1 · price: Each share of preferred stock is convertible at any time, at the holder's election, into shares of Class A Common Stock on a 4.675-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on June 20, 2024) and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of voting common stock (the "Common Stock") (the "IPO"), the shares of preferred stock reported herein automatically converted into the number of shares of Class A Common Stock in column 3. F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:35 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock, par value $0.00001 per share (Common Stock) | 1,560,000 | $9.00 | $14,040,000.00 |
DisclosureSEC source: 0000902664-23-005429 · ownership.xml · nonDerivative · entry 1 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,922,870 F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 20:30 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | PurchaseCommon Stock, par value $0.001 per share | 4,760,000 | $22.66 | $107,861,600.00 |
DisclosureSEC source: 0000902664-23-003642 · ownership.xml · nonDerivative · entry 1 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 13,959,973 F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:10 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 3,709,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-23-002975 · ownership.xml · derivative · entry 3 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,709,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:10 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 5,625,306 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-23-002975 · ownership.xml · derivative · entry 2 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 5,625,306 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F2 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:10 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | ConversionCommon Stock, par value $0.00001 per share ("Common Stock") | 9,334,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-23-002975 · ownership.xml · nonDerivative · entry 1 AyurMaya Capital Management Company, LP · CIK 0001975990 · Director · See Remarks GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,334,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F1 · price: Each share of preferred stock is convertible into one share of Common and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F3 · ownership.nature: The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:30 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock, par value $0.00001 per share ("Common Stock") | 1,250,000 | $12.00 | $15,000,000.00 |
DisclosureSEC source: 0000902664-22-005061 · ownership.xml · nonDerivative · entry 1 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,362,870 F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 20:44 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | ConversionSeries E Convertible Preferred Stock · Derivative | 2,327,870 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-21-004738 · ownership.xml · derivative · entry 3 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,327,870 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 20:44 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 1,785,000 | $14.00 | $24,990,000.00 |
DisclosureSEC source: 0000902664-21-004738 · ownership.xml · nonDerivative · entry 2 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,112,870 F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 20:44 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | ConversionCommon Stock, par value $0.00001 per share ("Common Stock") | 2,327,870 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-21-004738 · ownership.xml · nonDerivative · entry 1 Matrix Capital Management Company, LP · CIK 0001410830 · 10% owner GOEL DAVID E. · CIK 0001548144 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,327,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series E Convertible Preferred Stock was convertible at any time, at the holder's election on a 1-for-1 basis, and did not have an expiration date. The shares of Series E Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 30,268 | $42.38 | $1,282,664.01 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 9 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,309,090 F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 25,732 | $41.47 | $1,067,036.56 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 8 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,339,358 F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 34,302 | $41.16 | $1,411,887.47 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 7 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,365,090 F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 215,698 | $40.42 | $8,719,332.81 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 6 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,399,392 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 85,911 | $41.62 | $3,575,753.28 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 5 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,615,090 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 71,194 | $41.21 | $2,933,641.32 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 4 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,701,001 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 33,600 | $39.97 | $1,343,039.04 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 3 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,772,195 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 75,000 | $39.22 | $2,941,162.50 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 2 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,805,795 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 234,295 | $38.22 | $8,954,309.74 |
DisclosureSEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,880,795 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 02:40 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 3,759 | $0.00 Strike: $66.50 | $0.00 |
DisclosureSEC source: 0000902664-21-001476 · ownership.xml · derivative · entry 2 GOEL DAVID E. · CIK 0001548144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-15 F2 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. F1 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 02:40 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-21-001476 · ownership.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,000,000 | $40.00 | $80,000,000.00 |
DisclosureSEC source: 0000902664-20-002761 · ownership.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 13,115,090 F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| February 13, 2020 Filed May 11, 2020 20:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0000902664-20-002039 · ownership.xml · derivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. F2 · ownership.direct: The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. The Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Read SEC document |
| January 24, 2020 Filed Jan 28, 2020 21:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 2,217,101 | $26.50 | $58,753,176.50 |
DisclosureSEC source: 0000902664-20-000523 · ownership.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 15,115,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F2 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries F-1 Convertible Preferred Stock · Derivative | 84,359 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 8 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 84,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries F Convertible Preferred Stock · Derivative | 11,154,116 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 7 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 11,154,116 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries E-1 Convertible Preferred Stock · Derivative | 5,893,716 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 6 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 5,893,716 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries A Convertible Preferred Stock · Derivative | 200,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0000902664-19-002915 · ownership.xml · derivative · entry 5 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F1 · derivative.expiration_date: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 84,359 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 4 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 17,332,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 11,154,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 3 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 17,247,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 5,893,716 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 2 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 6,093,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:53 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-19-002915 · ownership.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director · 10% owner · See Remarks Matrix Capital Management Company, LP · CIK 0001410830 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 200,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the shares of convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The convertible preferred stock had no expiration date. F2 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. F3 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Read SEC document |
| May 08, 2018 Filed May 10, 2018 15:59 UTC | POPULAR, INC. BPOP · Entity 1363 | GrantCommon Stock Par Value $0.01 per share | 2,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-029101 · doc4.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,828.433 F1 · kind: Award of Restricted Stock pursuant to Popular, Inc.'s 2004 Omnibus Incentive Plan. The restriction of such restricted stock award lapses upon the retirement of the director. F2 · balance_after: Includes 122.79 shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act. Read SEC document |
| December 31, 2017 Filed Feb 12, 2018 21:38 UTC | POPULAR, INC. BPOP · Entity 1363 | OtherCommon Stock Par Value $0.01 per share | 120.643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009222 · doc5.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,572.643 F1 · kind: Shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act. Read SEC document |
| May 23, 2017 Filed May 24, 2017 17:29 UTC | POPULAR, INC. BPOP · Entity 1363 | GrantCommon Stock Par Value $0.01 per share | 2,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034853 · doc4.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,452 F1 · kind: Award of Restricted Stock pursuant to Popular, Inc.'s 2004 Omnibus Incentive Plan. The restriction of such restricted stock award lapses upon the retirement of the director. F2 · balance_after: Includes 69.935 shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act. Read SEC document |
| December 31, 2016 Filed Feb 13, 2017 12:08 UTC | POPULAR, INC. BPOP · Entity 1363 | OtherCommon Stock Par Value $0.01 per share | 66.202 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009816 · doc5.xml · nonDerivative · entry 1 GOEL DAVID E. · CIK 0001548144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,039.064 F1 · kind: Shares acquired pursuant to reinvestment of dividends paid by the Corporation and which are exempt under Section 16 of the Securities Exchange Act. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.